View ValuationColoplast 향후 성장Future 기준 점검 4/6Coloplast (는) 각각 연간 25.4% 및 6.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 24.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 35.9% 로 예상됩니다.핵심 정보25.4%이익 성장률24.68%EPS 성장률Medical Equipment 이익 성장16.3%매출 성장률6.4%향후 자기자본이익률35.89%애널리스트 커버리지Good마지막 업데이트19 Jun 2026최근 향후 성장 업데이트공시 • Feb 06Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2025-2026Coloplast A/S provided earnings guidance for the fiscal year 2025-2026. For the year, the company expects around 7% EBIT growth in constant currencies.공시 • Aug 20Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S re-affirmed earnings guidance for the fiscal year 2023/24. For the period, the company expects organic revenue growth to be around 8%. Reported growth in DKK is expected to be 10% to 11%.공시 • May 08+ 2 more updatesColoplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S revised earnings guidance for the fiscal year 2023/24. For the year, the company the organic revenue growth is still expected to be around 8%. Reported revenue growth in DKK is now expected to be 10-11%, from previously around 11%, and includes negative impact of 1-2%-points from currencies, from previously around 1%-point.공시 • Feb 09+ 1 more updateColoplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S reaffirmed earnings guidance for the fiscal year 2023/24. For the year, the organic revenue growth is still expected around 8% and continues to assume good momentum across business areas and regions.공시 • Nov 11+ 1 more updateColoplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024Coloplast A/S provided earnings guidance for Fiscal year 2023-2024. For the year company expects, organic revenue growth of around 8% and an EBIT margin of 27%-28%.공시 • Aug 17Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023Coloplast A/S provided earnings guidance for the fiscal year 2022/2023. Organic revenue growth continues to be expected around 8%. Reported revenue growth is still expected at 8% to 9%.모든 업데이트 보기Recent updates공시 • Jun 04Coloplast Announces FDA Approval of Titan Prime Inflatable Penile ProsthesisColoplast announced FDA approval of Titan Prime, an inflatable penile prosthesis (IPP) that represents the company’s next-generation device and will be available in the U.S. in late 2026. Around 30 million men in the US experience ongoing difficulty in getting or keeping an erection firm enough for sexual activity. As an alternative to medication, some benefit from long-term treatment options such as an inflatable penile prosthesis, which is delivered through a single outpatient procedure. Inflatable Penile Prosthesis Titan Prime IPP is designed to emulate the appearance and performance of a natural erection, supporting device performance for patients, surgeons, and partners. Built with proprietary Bioflex – a polymer engineered for greater strength and durability than silicone – Titan Prime IPP delivers greater material strength than leading silicone competitors and withstands higher pressures to reinforce reliability. Titan Prime IPP preserves the rigidity and girth surgeons trust from Titan IPP today, while providing improved flaccid flexibility for comfort and concealability. The result is consistent, predictable outcomes across diverse male anatomies. Titan Prime is now FDA-approved and will be available through a phased launch to urologists and health care systems in the United States beginning in late 2026. Titan Prime IPP is approved for use in the United States by the FDA. Coloplast is pursuing regulatory approvals in other countries, where the product is not yet available.공시 • May 13Coloplast A/S Announces Interim Dividend for the First Half Ended March 31, 2026Coloplast A/S announced that it will pay a interim dividend of DKK 5.00 per share, for a total dividend pay-out of DKK 1,127 million for the first half ended March 31, 2026.공시 • Mar 07Coloplast A/S Announces President ChangesColoplast A/S's board of directors announced the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026. Gavin Wood will take over from interim CEO Lars Rasmussen, who has been in the role since May 5, 2025. Gavin Wood has spent two decades in different leadership roles in Johnson & Johnson, most recently as Company Group Chairman of Johnson & Johnson MedTech EMEA, a multi-billion-dollar business with more than 7,000 employees working across three business units: Surgery, Orthopedics, and Cardiovascular & Specialty Solutions. Earlier in his career, he led the Ethicon Wound Closure & Healing team as Worldwide President, and prior to that, he served as Executive Vice President, Commercial, at Mölnlycke. Gavin Wood currently serves as Vice Chair of the MedTech Europe trade association. He holds a Bachelor of Arts degree in Law from Carleton University, Canada and an MBA from Queen’s University, Canada. He is Canadian by birth, currently lives in Switzerland, and he will be relocating to Denmark. Lars Rasmussen will continue to lead Coloplast as interim CEO until the end of April.공시 • Mar 06Coloplast A/S Announces CEO ChangesColoplast A/S's board of directors announced the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026. Gavin Wood will take over from interim CEO Lars Rasmussen, who has been in the role since May 5, 2025. Gavin Wood has spent two decades in different leadership roles in Johnson & Johnson, most recently as Company Group Chairman of Johnson & Johnson MedTech EMEA, a multi-billion-dollar business with more than 7,000 employees working across three business units: Surgery, Orthopedics, and Cardiovascular & Specialty Solutions. Earlier in his career, he led the Ethicon Wound Closure & Healing team as Worldwide President, and prior to that, he served as Executive Vice President, Commercial, at Mölnlycke. Gavin Wood currently serves as Vice Chair of the MedTech Europe trade association. He holds a Bachelor of Arts degree in Law from Carleton University, Canada and an MBA from Queen’s University, Canada. He is Canadian by birth, currently lives in Switzerland, and he will be relocating to Denmark. Lars Rasmussen will continue to lead Coloplast as interim CEO until the end of April.공시 • Feb 06Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2025-2026Coloplast A/S provided earnings guidance for the fiscal year 2025-2026. For the year, the company expects around 7% EBIT growth in constant currencies.공시 • Dec 19Coloplast A/S Announces Executive ChangesColoplast A/S announced changes to its Executive Leadership Team, affecting the Interventional Urology business and the global People & Culture function. Executive Vice President of People & Culture, Dorthe Rønnau, has decided to leave Coloplast to pursue the next chapter in her career. She has spent close to three decades in different roles across the Coloplast Group, including Global Operations, Atos, and People & Culture, and in her role in the Executive Leadership Team. An external search is currently on-going to identify a new leader of the global People & Culture function. Dorthe Rønnau will have her last day at Coloplast at the end of February 2026, where Mads Mikkelsen, Vice President, People & Culture, Chronic Care Commercial, will take over the interim leadership of the global People & Culture organisation until a permanent successor has been identified. After more than a decade in Coloplast and more than three decades in the global life science industry, Tommy Johns, Executive Vice President of Interventional Urology, will retire early next year. Tommy Johns has been instrumental in identifying his successor, ensuring a period of overlap between Tommy and his successor to ensure a thorough handover prior to Tommy’s final day with Coloplast early next year. Kevin Hardage will step into the role of Executive Vice President of Interventional Urology. He joins Coloplast on February 9, 2026. Kevin brings extensive experience from the global MedTech industry, including senior leadership experience from Teleflex in the urology space.공시 • Dec 05+ 2 more updatesColoplast A/S Approves Interim Dividend for the Year 2025Coloplast A/S approved at its AGM held on 4 December 2025 interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with Coloplast A/S’ half- year result, this brings the total dividend paid for the financial year 2024/25 to DKK 23.00 per share of nominally DKK 1.공시 • Nov 04+ 1 more updateColoplast A/S Recommends Year-End DividendThe Board of Directors of Coloplast A/S recommended a year-end dividend of DKK 18.00 per share, which brings the total dividend for the year to DKK 23.00 per share, compared to DKK 22.00 per share last year.공시 • Oct 09Coloplast A/S Announces Interim CEO Lars Rasmussen Will Step Down from the Board At the Upcoming Annual General Meeting on December 4, 2025Coloplast interim CEO Lars Rasmussen has informed the Coloplast Board of Directors that he will not stand for re-election as board member at the upcoming annual general meeting on December 4, 2025. Lars Rasmussen will, as announced earlier this year, continue in the role as interim CEO until a new CEO of Coloplast is in place. Jette Nygaard-Andersen will continue in the role of interim Chair and, together with the Board of Directors, lead Coloplast in the coming period, as the company enters into its next strategic period of long-term, sustainable growth and value creation. Jette Nygaard-Andersen has been a member of the Board since December 2015 and interim Chair since May 5, 2025. The Board of Directors are unanimously supportive of the announced changes. The search for Coloplast’s new CEO is progressing according to plan, and an announcement will follow once a decision has been made.공시 • Oct 01Coloplast A/S, Annual General Meeting, Dec 03, 2026Coloplast A/S, Annual General Meeting, Dec 03, 2026.공시 • Sep 30+ 3 more updatesColoplast A/S to Report Fiscal Year 2026 Results on Nov 05, 2026Coloplast A/S announced that they will report fiscal year 2026 results at 7:30 AM, Central European Standard Time on Nov 05, 2026공시 • May 06+ 1 more updateColoplast A/S Announces CEO ChangesColoplast A/S announced that CEO Kristian Villumsen has stepped down from his position as of May 5, 2025. The Board of Directors has appointed Lars Rasmussen as interim CEO. As the company enters a new strategy period, the Board has initiated the search for a new CEO to lead Coloplast into its next phase of long-term, sustainable growth and value creation. To ensure continuity, the Chair of the Board Lars Rasmussen assumes the role as interim CEO. Accordingly, Lars Rasmussen steps down as Chair and will serve as an ordinary member of the Board. The new CEO of Coloplast is expected to be in place within the next 12 months, during which Lars Rasmussen will work closely with the executive leadership team to ensure continuity and accelerate momentum. He brings deep knowledge of Coloplast, having served as President & CEO from 2008 to 2018 and as part of executive management since 2001. During his tenure as interim CEO and ordinary Board member, Lars Rasmussen will step down as Chair of the Remuneration and Nomination Committee and as a member of the Audit Committee. Jette Nygaard-Andersen will assume these responsibilities during this period.공시 • Dec 05An undisclosed buyer acquired Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B).An undisclosed buyer acquired Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B) on December 3, 2024. For the period ending September 30, 2024, Coloplast's Skin Care business reported total revenue of DKK 400 million. An undisclosed buyer completed the acquisition of Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B) on December 3, 2024.공시 • Nov 15Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD PolicyColoplast A/S announced on 14 November 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a final Local Coverage Determination (LCD) policy regarding skin substitute grafts/cellular and tissue-based products for the treatment of Diabetic Foot Ulcers (DFUs) and venous leg ulcers (VLUs) in the Medicare population. The final LCD policy confirms the introduction of a technical qualification and a clinical efficacy qualification, proposed in a draft LCD policy2 earlier this year. The final decision also introduces two separate lists for covered products for DFUs and covered products for VLUs. In addition, the application limit has been expanded from 4 to 8 and the duration of treatment has been increased from 12 to 16 weeks in the final policy. The implementation date of the final policy is set to 12 February 2025. Based on the final evaluation, Kerecis is included on the final list of covered products for DFUs, however, Kerecis has not been included on the covered list for VLUs. Sales related to VLUs in the out-patient setting currently represent a low-single digit portion of the total Kerecis’ sales. Kerecis has an ongoing clinical study on VLUs and will attempt to get coverage for VLUs as soon as the study is completed.공시 • Nov 06Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025Coloplast A/S announced that they will report nine months, 2025 results on Aug 19, 2025공시 • Nov 05+ 2 more updatesColoplast A/S Recommends the Distribution of Year-End DividendThe Board of Directors of Coloplast A/S recommended a year-end dividend of DKK 17.00 per share, which brings the total dividend for the year to DKK 22.00 per share, compared to DKK 21.00 per share last year.공시 • Oct 15+ 2 more updatesColoplast A/S to Report First Half, 2025 Results on May 06, 2025Coloplast A/S announced that they will report first half, 2025 results on May 06, 2025공시 • Sep 27Coloplast A/S, Annual General Meeting, Dec 04, 2025Coloplast A/S, Annual General Meeting, Dec 04, 2025.공시 • Aug 20Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S re-affirmed earnings guidance for the fiscal year 2023/24. For the period, the company expects organic revenue growth to be around 8%. Reported growth in DKK is expected to be 10% to 11%.공시 • May 08+ 2 more updatesColoplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S revised earnings guidance for the fiscal year 2023/24. For the year, the company the organic revenue growth is still expected to be around 8%. Reported revenue growth in DKK is now expected to be 10-11%, from previously around 11%, and includes negative impact of 1-2%-points from currencies, from previously around 1%-point.공시 • Feb 09+ 1 more updateColoplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S reaffirmed earnings guidance for the fiscal year 2023/24. For the year, the organic revenue growth is still expected around 8% and continues to assume good momentum across business areas and regions.공시 • Feb 01Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the USColoplast A/S aims to expand its position within advanced wound care by introducing a new silicone foam that will benefit both healthcare professionals and patients. Changing demographics and an aging population are leading to a higher demand for healthcare services, putting significant strain on healthcare systems. In the US, chronic wounds are reported to affect 10.5 million patients annually1, while 2.5 million patients develop a pressure injury in acute care facilities each year2. Therefore, it is critical for healthcare providers to choose products that simplify their workflows and deliver the best possible care for their patients.공시 • Dec 08Coloplast A/S Approves the Distribution of Year-End DividendColoplast A/S approved the distribution of year-end dividend of DKK 16 per share of nominally DKK 1, at the AGM held on December 7, 2023.공시 • Nov 11+ 1 more updateColoplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024Coloplast A/S provided earnings guidance for Fiscal year 2023-2024. For the year company expects, organic revenue growth of around 8% and an EBIT margin of 27%-28%.공시 • Sep 10+ 4 more updatesColoplast A/S to Report Q1, 2024 Results on Feb 09, 2024Coloplast A/S announced that they will report Q1, 2024 results at 7:30 AM, Central European Standard Time on Feb 09, 2024공시 • Sep 02Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLCColoplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion on July 7, 2023. The total enterprise value for 100% ownership of Kerecis amounts to up to $1.3 billion, consisting of $1.2 billion upfront cash payment and an earnout potential of maximum $100 million dependent on financial performance in FY 2023/24. The transaction is expected to be financed through an equity capital raise of around DKK 9 billion ($1.3 billion). Following the expected acquisition, Kerecis will operate as a stand-alone business unit under its own identity and brand. Kerecis reported a revenue of DKK 510 million ($74.36 million) in FY 2021/22. Closing of the transaction is subject to customary regulatory approvals and an acceptance threshold of at least 90%, and is anticipated in Q4 2022/23. Kerecis’ Board of Directors has recommended to the company’s minority shareholders to sell their shares in Kerecis to Coloplast. 77% of Kerecis’ shareholders have committed to sell their shares to Coloplast. The acquisition is expected to be margin dilutive short-term for Coloplast. The transaction is expected to be increasingly EPS accretive from FY 2026/27. Coloplast’s financial guidance for FY 2022/23 excluding transaction related costs is unchanged. Special items for FY 2022/23 are expected to increase by DKK 50 million due to transaction related costs (advisory fees). Ulrik Falk, Morten Sløk and Niklas Mortensen of FIH Partners acted as financial advisors to Coloplast A/S. Jeppe Buskov, Morten Kofmann and Oliver Machholdt of Kromann Reumert acted as Lead Legal Advisor and PWC acted as financial advisor to Coloplast. Danske Bank will act as Sole Global Coordinator in connection with the equity capital raise and Joint Bookrunner together with Nordea. J.P. Morgan acted as exclusive financial advisor to Kerecis. Logos Legal Services advised Kerecis on Icelandic law matters. Mark P. Holloway, Michael C. Labriola, Ross Davies, Sarah Lane, Stephen R. Heifetz, Michael S. Casey, Anne E. Seymour, Beau Buffier, Kimberley Biagioli, Andrew Poling, Martin Luff, Matt Staples and Paul S. Gadiock of Wilson Sonsini Goodrich & Rosati, P.C. acted as legal advisor to Kerecis. Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC on August 31, 2023.공시 • Aug 17Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023Coloplast A/S provided earnings guidance for the fiscal year 2022/2023. Organic revenue growth continues to be expected around 8%. Reported revenue growth is still expected at 8% to 9%.공시 • Jul 08Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion on July 7, 2023. The total enterprise value for 100% ownership of Kerecis amounts to up to $1.3 billion, consisting of $1.2 billion upfront cash payment and an earnout potential of maximum $100 million dependent on financial performance in FY 2023/24. The transaction is expected to be financed through an equity capital raise of around DKK 9 billion ($1.3 billion). Following the expected acquisition, Kerecis will operate as a stand-alone business unit under its own identity and brand. Kerecis reported a revenue of DKK 510 million ($74.36 million) in FY 2021/22. Closing of the transaction is subject to customary regulatory approvals and an acceptance threshold of at least 90%, and is anticipated in Q4 2022/23. Kerecis’ Board of Directors has recommended to the company’s minority shareholders to sell their shares in Kerecis to Coloplast. 77% of Kerecis’ shareholders have committed to sell their shares to Coloplast. The acquisition is expected to be margin dilutive short-term for Coloplast. The transaction is expected to be increasingly EPS accretive from FY 2026/27. Coloplast’s financial guidance for FY 2022/23 excluding transaction related costs is unchanged. Special items for FY 2022/23 are expected to increase by DKK 50 million due to transaction related costs (advisory fees).FIH Partners acted as transaction advisors, Kromann Reumert acted as Lead Legal Advisors, and PWC acted as financial advisors to Coloplast. Danske Bank will act as Sole Global Coordinator in connection with the equity capital raise and Joint Bookrunner together with Nordea. J.P. Morgan acted as exclusive financial advisor to Kerecis.공시 • May 11Coloplast A/S Provides Earnings Guidance for the Fiscal 2023Coloplast A/S provided earnings guidance for the full fiscal year 2022/2023. For the period, the company reports organic revenue growth is now expected around 8% in constant exchange rates, from 7-8% previously. Reported growth in DKK is now expected to be 8-9%, from previously 9-10%, due to negative impact from currencies. Consequently, the reported EBIT margin is now expected in the 28-29% range, from previously 28-30%.공시 • Feb 04Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract InfectionsColoplast launches male catheter designed to reduce the risk of urinary tract infections. The new intermittent catheter Luja addresses important risk factors for urinary tract infections, a significant burden for people using intermittent catheters as well as healthcare systems as a whole. Urinary tract infections represent a significant challenge for people who use intermittent catheters to empty their bladder. This includes people living with spinal cord injury, multiple sclerosis, or spina bifida. On average, intermittent catheter users have 2-3 urinary tract infections per year1-3, which can lead to serious health complications4, have a significant impact on quality of life2, and result in hospitalisation5-9, thereby putting pressure on local healthcare systems. Coloplast is now launching Luja, the first and only male catheter featuring 80+ micro-holes, aiming to address important UTI risk factors1 linked to intermittent catheterisation. Flow stops and blockage of the catheter eyelets during emptying increase the risk of leaving residual urine behind in the bladder. Residual urine increases the risk of bacteria growth and is a well-known UTI risk factor. The launch of Luja begins this month, February, in Denmark and Finland, and the product is expected to be available across Coloplast’s key markets over the next 12 months. Coloplast is currently conducting two pivotal clinical studies to document and demonstrate the benefits of Luja. The results are expected to be publicly available within the next few months. In 2021/22, the global market for continence care products was worth an estimated 15-16 billion DKK with an underlying annual market growth of 5-6%. Coloplast is the global market leader in continence care, and the company continues to outgrow the market and take market share. The launch of Luja is expected to contribute to Coloplast’s growth trajectory and help solidify the company’s global market leader position. Luja has close to no flow stops and complete bladder emptying is defined as <10 mL (CP353, NCT05485922).공시 • Feb 03Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23Coloplast A/S provided earnings guidance for the Fiscal Year 2022/23. For the period, Organic revenue growth is expected at 7% to 8% in constant exchange rates. Reported EBIT margin before special items is still expected at 28% to 30%, impacted by increasing input costs, especially raw materials and electricity in Hungary, partly offset by leverage, efficiency gains and prudent management of operating costs.공시 • Sep 09+ 4 more updatesColoplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023Coloplast A/S announced that they will report fiscal year 2023 results on Nov 09, 2023이익 및 매출 성장 예측OTCPK:CLPB.Y - 애널리스트 향후 추정치 및 과거 재무 데이터 (DKK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수9/30/202832,7096,4986,0407,509199/30/202730,7125,9615,5376,944209/30/202628,7373,1545,5886,412193/31/202628,0452,1065,9237,595N/A12/31/202527,8913,9895,3386,871N/A9/30/202527,8743,6365,2186,645N/A6/30/202527,8674,0754,9486,428N/A3/31/202527,7944,5444,8736,287N/A12/31/202427,4504,8841,6072,985N/A9/30/202427,0305,0521,4202,766N/A6/30/202426,3034,9671,3132,599N/A3/31/202425,5264,9651,0532,278N/A12/31/202325,0014,8684,2855,527N/A9/30/202324,5004,7832,9854,226N/A6/30/202324,3334,7843,2264,485N/A3/31/202324,0744,8013,6634,894N/A12/31/202223,5154,6263,2464,455N/A9/30/202222,5794,7063,9645,099N/A6/30/202221,6204,7813,8944,913N/A3/31/202220,6064,7463,7354,712N/A12/31/202119,8574,8964,2725,209N/A9/30/202119,4264,8253,3245,290N/A6/30/202118,9164,5613,1025,023N/A3/31/202118,5004,3043,1625,077N/A12/31/202018,5704,2413,0034,941N/A9/30/202018,5444,1973,8284,759N/A6/30/202018,5723,9493,8764,842N/A3/31/202018,7524,0203,8724,764N/A12/31/201918,3303,974N/A4,615N/A9/30/201917,9393,873N/A4,357N/A6/30/201917,5554,119N/A4,161N/A3/31/201917,1813,999N/A4,177N/A12/31/201816,8153,896N/A4,126N/A9/30/201816,4493,845N/A4,361N/A6/30/201816,1953,816N/A4,370N/A3/31/201815,8823,778N/A4,111N/A12/31/201715,7283,791N/A4,004N/A9/30/201715,5283,797N/A3,251N/A6/30/201715,2873,211N/A2,994N/A3/31/201715,0613,279N/A2,492N/A12/31/201614,7803,264N/A2,653N/A9/30/201614,6813,143N/A3,028N/A6/30/201614,5631,297N/A3,081N/A3/31/201614,4171,028N/A3,568N/A12/31/201514,264927N/A3,320N/A9/30/201513,909899N/A3,337N/A6/30/201513,5023,162N/A3,119N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: CLPB.Y 의 연간 예상 수익 증가율(25.4%)이 saving rate(3.5%)보다 높습니다.수익 vs 시장: CLPB.Y 의 연간 수익(25.4%)이 US 시장(18.9%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: CLPB.Y 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: CLPB.Y 의 수익(연간 6.4%)이 US 시장(연간 13%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: CLPB.Y 의 수익(연간 6.4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: CLPB.Y의 자본 수익률은 3년 후 35.9%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/22 11:29종가2026/06/22 00:00수익2026/03/31연간 수익2025/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Coloplast A/S는 40명의 분석가가 다루고 있습니다. 이 중 20명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullABG Sundal CollierHassan Al-WakeelBarclaysAlexander KlebanBarclays37명의 분석가 더 보기
공시 • Feb 06Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2025-2026Coloplast A/S provided earnings guidance for the fiscal year 2025-2026. For the year, the company expects around 7% EBIT growth in constant currencies.
공시 • Aug 20Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S re-affirmed earnings guidance for the fiscal year 2023/24. For the period, the company expects organic revenue growth to be around 8%. Reported growth in DKK is expected to be 10% to 11%.
공시 • May 08+ 2 more updatesColoplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S revised earnings guidance for the fiscal year 2023/24. For the year, the company the organic revenue growth is still expected to be around 8%. Reported revenue growth in DKK is now expected to be 10-11%, from previously around 11%, and includes negative impact of 1-2%-points from currencies, from previously around 1%-point.
공시 • Feb 09+ 1 more updateColoplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S reaffirmed earnings guidance for the fiscal year 2023/24. For the year, the organic revenue growth is still expected around 8% and continues to assume good momentum across business areas and regions.
공시 • Nov 11+ 1 more updateColoplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024Coloplast A/S provided earnings guidance for Fiscal year 2023-2024. For the year company expects, organic revenue growth of around 8% and an EBIT margin of 27%-28%.
공시 • Aug 17Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023Coloplast A/S provided earnings guidance for the fiscal year 2022/2023. Organic revenue growth continues to be expected around 8%. Reported revenue growth is still expected at 8% to 9%.
공시 • Jun 04Coloplast Announces FDA Approval of Titan Prime Inflatable Penile ProsthesisColoplast announced FDA approval of Titan Prime, an inflatable penile prosthesis (IPP) that represents the company’s next-generation device and will be available in the U.S. in late 2026. Around 30 million men in the US experience ongoing difficulty in getting or keeping an erection firm enough for sexual activity. As an alternative to medication, some benefit from long-term treatment options such as an inflatable penile prosthesis, which is delivered through a single outpatient procedure. Inflatable Penile Prosthesis Titan Prime IPP is designed to emulate the appearance and performance of a natural erection, supporting device performance for patients, surgeons, and partners. Built with proprietary Bioflex – a polymer engineered for greater strength and durability than silicone – Titan Prime IPP delivers greater material strength than leading silicone competitors and withstands higher pressures to reinforce reliability. Titan Prime IPP preserves the rigidity and girth surgeons trust from Titan IPP today, while providing improved flaccid flexibility for comfort and concealability. The result is consistent, predictable outcomes across diverse male anatomies. Titan Prime is now FDA-approved and will be available through a phased launch to urologists and health care systems in the United States beginning in late 2026. Titan Prime IPP is approved for use in the United States by the FDA. Coloplast is pursuing regulatory approvals in other countries, where the product is not yet available.
공시 • May 13Coloplast A/S Announces Interim Dividend for the First Half Ended March 31, 2026Coloplast A/S announced that it will pay a interim dividend of DKK 5.00 per share, for a total dividend pay-out of DKK 1,127 million for the first half ended March 31, 2026.
공시 • Mar 07Coloplast A/S Announces President ChangesColoplast A/S's board of directors announced the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026. Gavin Wood will take over from interim CEO Lars Rasmussen, who has been in the role since May 5, 2025. Gavin Wood has spent two decades in different leadership roles in Johnson & Johnson, most recently as Company Group Chairman of Johnson & Johnson MedTech EMEA, a multi-billion-dollar business with more than 7,000 employees working across three business units: Surgery, Orthopedics, and Cardiovascular & Specialty Solutions. Earlier in his career, he led the Ethicon Wound Closure & Healing team as Worldwide President, and prior to that, he served as Executive Vice President, Commercial, at Mölnlycke. Gavin Wood currently serves as Vice Chair of the MedTech Europe trade association. He holds a Bachelor of Arts degree in Law from Carleton University, Canada and an MBA from Queen’s University, Canada. He is Canadian by birth, currently lives in Switzerland, and he will be relocating to Denmark. Lars Rasmussen will continue to lead Coloplast as interim CEO until the end of April.
공시 • Mar 06Coloplast A/S Announces CEO ChangesColoplast A/S's board of directors announced the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026. Gavin Wood will take over from interim CEO Lars Rasmussen, who has been in the role since May 5, 2025. Gavin Wood has spent two decades in different leadership roles in Johnson & Johnson, most recently as Company Group Chairman of Johnson & Johnson MedTech EMEA, a multi-billion-dollar business with more than 7,000 employees working across three business units: Surgery, Orthopedics, and Cardiovascular & Specialty Solutions. Earlier in his career, he led the Ethicon Wound Closure & Healing team as Worldwide President, and prior to that, he served as Executive Vice President, Commercial, at Mölnlycke. Gavin Wood currently serves as Vice Chair of the MedTech Europe trade association. He holds a Bachelor of Arts degree in Law from Carleton University, Canada and an MBA from Queen’s University, Canada. He is Canadian by birth, currently lives in Switzerland, and he will be relocating to Denmark. Lars Rasmussen will continue to lead Coloplast as interim CEO until the end of April.
공시 • Feb 06Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2025-2026Coloplast A/S provided earnings guidance for the fiscal year 2025-2026. For the year, the company expects around 7% EBIT growth in constant currencies.
공시 • Dec 19Coloplast A/S Announces Executive ChangesColoplast A/S announced changes to its Executive Leadership Team, affecting the Interventional Urology business and the global People & Culture function. Executive Vice President of People & Culture, Dorthe Rønnau, has decided to leave Coloplast to pursue the next chapter in her career. She has spent close to three decades in different roles across the Coloplast Group, including Global Operations, Atos, and People & Culture, and in her role in the Executive Leadership Team. An external search is currently on-going to identify a new leader of the global People & Culture function. Dorthe Rønnau will have her last day at Coloplast at the end of February 2026, where Mads Mikkelsen, Vice President, People & Culture, Chronic Care Commercial, will take over the interim leadership of the global People & Culture organisation until a permanent successor has been identified. After more than a decade in Coloplast and more than three decades in the global life science industry, Tommy Johns, Executive Vice President of Interventional Urology, will retire early next year. Tommy Johns has been instrumental in identifying his successor, ensuring a period of overlap between Tommy and his successor to ensure a thorough handover prior to Tommy’s final day with Coloplast early next year. Kevin Hardage will step into the role of Executive Vice President of Interventional Urology. He joins Coloplast on February 9, 2026. Kevin brings extensive experience from the global MedTech industry, including senior leadership experience from Teleflex in the urology space.
공시 • Dec 05+ 2 more updatesColoplast A/S Approves Interim Dividend for the Year 2025Coloplast A/S approved at its AGM held on 4 December 2025 interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with Coloplast A/S’ half- year result, this brings the total dividend paid for the financial year 2024/25 to DKK 23.00 per share of nominally DKK 1.
공시 • Nov 04+ 1 more updateColoplast A/S Recommends Year-End DividendThe Board of Directors of Coloplast A/S recommended a year-end dividend of DKK 18.00 per share, which brings the total dividend for the year to DKK 23.00 per share, compared to DKK 22.00 per share last year.
공시 • Oct 09Coloplast A/S Announces Interim CEO Lars Rasmussen Will Step Down from the Board At the Upcoming Annual General Meeting on December 4, 2025Coloplast interim CEO Lars Rasmussen has informed the Coloplast Board of Directors that he will not stand for re-election as board member at the upcoming annual general meeting on December 4, 2025. Lars Rasmussen will, as announced earlier this year, continue in the role as interim CEO until a new CEO of Coloplast is in place. Jette Nygaard-Andersen will continue in the role of interim Chair and, together with the Board of Directors, lead Coloplast in the coming period, as the company enters into its next strategic period of long-term, sustainable growth and value creation. Jette Nygaard-Andersen has been a member of the Board since December 2015 and interim Chair since May 5, 2025. The Board of Directors are unanimously supportive of the announced changes. The search for Coloplast’s new CEO is progressing according to plan, and an announcement will follow once a decision has been made.
공시 • Oct 01Coloplast A/S, Annual General Meeting, Dec 03, 2026Coloplast A/S, Annual General Meeting, Dec 03, 2026.
공시 • Sep 30+ 3 more updatesColoplast A/S to Report Fiscal Year 2026 Results on Nov 05, 2026Coloplast A/S announced that they will report fiscal year 2026 results at 7:30 AM, Central European Standard Time on Nov 05, 2026
공시 • May 06+ 1 more updateColoplast A/S Announces CEO ChangesColoplast A/S announced that CEO Kristian Villumsen has stepped down from his position as of May 5, 2025. The Board of Directors has appointed Lars Rasmussen as interim CEO. As the company enters a new strategy period, the Board has initiated the search for a new CEO to lead Coloplast into its next phase of long-term, sustainable growth and value creation. To ensure continuity, the Chair of the Board Lars Rasmussen assumes the role as interim CEO. Accordingly, Lars Rasmussen steps down as Chair and will serve as an ordinary member of the Board. The new CEO of Coloplast is expected to be in place within the next 12 months, during which Lars Rasmussen will work closely with the executive leadership team to ensure continuity and accelerate momentum. He brings deep knowledge of Coloplast, having served as President & CEO from 2008 to 2018 and as part of executive management since 2001. During his tenure as interim CEO and ordinary Board member, Lars Rasmussen will step down as Chair of the Remuneration and Nomination Committee and as a member of the Audit Committee. Jette Nygaard-Andersen will assume these responsibilities during this period.
공시 • Dec 05An undisclosed buyer acquired Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B).An undisclosed buyer acquired Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B) on December 3, 2024. For the period ending September 30, 2024, Coloplast's Skin Care business reported total revenue of DKK 400 million. An undisclosed buyer completed the acquisition of Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B) on December 3, 2024.
공시 • Nov 15Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD PolicyColoplast A/S announced on 14 November 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a final Local Coverage Determination (LCD) policy regarding skin substitute grafts/cellular and tissue-based products for the treatment of Diabetic Foot Ulcers (DFUs) and venous leg ulcers (VLUs) in the Medicare population. The final LCD policy confirms the introduction of a technical qualification and a clinical efficacy qualification, proposed in a draft LCD policy2 earlier this year. The final decision also introduces two separate lists for covered products for DFUs and covered products for VLUs. In addition, the application limit has been expanded from 4 to 8 and the duration of treatment has been increased from 12 to 16 weeks in the final policy. The implementation date of the final policy is set to 12 February 2025. Based on the final evaluation, Kerecis is included on the final list of covered products for DFUs, however, Kerecis has not been included on the covered list for VLUs. Sales related to VLUs in the out-patient setting currently represent a low-single digit portion of the total Kerecis’ sales. Kerecis has an ongoing clinical study on VLUs and will attempt to get coverage for VLUs as soon as the study is completed.
공시 • Nov 06Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025Coloplast A/S announced that they will report nine months, 2025 results on Aug 19, 2025
공시 • Nov 05+ 2 more updatesColoplast A/S Recommends the Distribution of Year-End DividendThe Board of Directors of Coloplast A/S recommended a year-end dividend of DKK 17.00 per share, which brings the total dividend for the year to DKK 22.00 per share, compared to DKK 21.00 per share last year.
공시 • Oct 15+ 2 more updatesColoplast A/S to Report First Half, 2025 Results on May 06, 2025Coloplast A/S announced that they will report first half, 2025 results on May 06, 2025
공시 • Sep 27Coloplast A/S, Annual General Meeting, Dec 04, 2025Coloplast A/S, Annual General Meeting, Dec 04, 2025.
공시 • Aug 20Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S re-affirmed earnings guidance for the fiscal year 2023/24. For the period, the company expects organic revenue growth to be around 8%. Reported growth in DKK is expected to be 10% to 11%.
공시 • May 08+ 2 more updatesColoplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S revised earnings guidance for the fiscal year 2023/24. For the year, the company the organic revenue growth is still expected to be around 8%. Reported revenue growth in DKK is now expected to be 10-11%, from previously around 11%, and includes negative impact of 1-2%-points from currencies, from previously around 1%-point.
공시 • Feb 09+ 1 more updateColoplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S reaffirmed earnings guidance for the fiscal year 2023/24. For the year, the organic revenue growth is still expected around 8% and continues to assume good momentum across business areas and regions.
공시 • Feb 01Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the USColoplast A/S aims to expand its position within advanced wound care by introducing a new silicone foam that will benefit both healthcare professionals and patients. Changing demographics and an aging population are leading to a higher demand for healthcare services, putting significant strain on healthcare systems. In the US, chronic wounds are reported to affect 10.5 million patients annually1, while 2.5 million patients develop a pressure injury in acute care facilities each year2. Therefore, it is critical for healthcare providers to choose products that simplify their workflows and deliver the best possible care for their patients.
공시 • Dec 08Coloplast A/S Approves the Distribution of Year-End DividendColoplast A/S approved the distribution of year-end dividend of DKK 16 per share of nominally DKK 1, at the AGM held on December 7, 2023.
공시 • Nov 11+ 1 more updateColoplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024Coloplast A/S provided earnings guidance for Fiscal year 2023-2024. For the year company expects, organic revenue growth of around 8% and an EBIT margin of 27%-28%.
공시 • Sep 10+ 4 more updatesColoplast A/S to Report Q1, 2024 Results on Feb 09, 2024Coloplast A/S announced that they will report Q1, 2024 results at 7:30 AM, Central European Standard Time on Feb 09, 2024
공시 • Sep 02Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLCColoplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion on July 7, 2023. The total enterprise value for 100% ownership of Kerecis amounts to up to $1.3 billion, consisting of $1.2 billion upfront cash payment and an earnout potential of maximum $100 million dependent on financial performance in FY 2023/24. The transaction is expected to be financed through an equity capital raise of around DKK 9 billion ($1.3 billion). Following the expected acquisition, Kerecis will operate as a stand-alone business unit under its own identity and brand. Kerecis reported a revenue of DKK 510 million ($74.36 million) in FY 2021/22. Closing of the transaction is subject to customary regulatory approvals and an acceptance threshold of at least 90%, and is anticipated in Q4 2022/23. Kerecis’ Board of Directors has recommended to the company’s minority shareholders to sell their shares in Kerecis to Coloplast. 77% of Kerecis’ shareholders have committed to sell their shares to Coloplast. The acquisition is expected to be margin dilutive short-term for Coloplast. The transaction is expected to be increasingly EPS accretive from FY 2026/27. Coloplast’s financial guidance for FY 2022/23 excluding transaction related costs is unchanged. Special items for FY 2022/23 are expected to increase by DKK 50 million due to transaction related costs (advisory fees). Ulrik Falk, Morten Sløk and Niklas Mortensen of FIH Partners acted as financial advisors to Coloplast A/S. Jeppe Buskov, Morten Kofmann and Oliver Machholdt of Kromann Reumert acted as Lead Legal Advisor and PWC acted as financial advisor to Coloplast. Danske Bank will act as Sole Global Coordinator in connection with the equity capital raise and Joint Bookrunner together with Nordea. J.P. Morgan acted as exclusive financial advisor to Kerecis. Logos Legal Services advised Kerecis on Icelandic law matters. Mark P. Holloway, Michael C. Labriola, Ross Davies, Sarah Lane, Stephen R. Heifetz, Michael S. Casey, Anne E. Seymour, Beau Buffier, Kimberley Biagioli, Andrew Poling, Martin Luff, Matt Staples and Paul S. Gadiock of Wilson Sonsini Goodrich & Rosati, P.C. acted as legal advisor to Kerecis. Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC on August 31, 2023.
공시 • Aug 17Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023Coloplast A/S provided earnings guidance for the fiscal year 2022/2023. Organic revenue growth continues to be expected around 8%. Reported revenue growth is still expected at 8% to 9%.
공시 • Jul 08Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion on July 7, 2023. The total enterprise value for 100% ownership of Kerecis amounts to up to $1.3 billion, consisting of $1.2 billion upfront cash payment and an earnout potential of maximum $100 million dependent on financial performance in FY 2023/24. The transaction is expected to be financed through an equity capital raise of around DKK 9 billion ($1.3 billion). Following the expected acquisition, Kerecis will operate as a stand-alone business unit under its own identity and brand. Kerecis reported a revenue of DKK 510 million ($74.36 million) in FY 2021/22. Closing of the transaction is subject to customary regulatory approvals and an acceptance threshold of at least 90%, and is anticipated in Q4 2022/23. Kerecis’ Board of Directors has recommended to the company’s minority shareholders to sell their shares in Kerecis to Coloplast. 77% of Kerecis’ shareholders have committed to sell their shares to Coloplast. The acquisition is expected to be margin dilutive short-term for Coloplast. The transaction is expected to be increasingly EPS accretive from FY 2026/27. Coloplast’s financial guidance for FY 2022/23 excluding transaction related costs is unchanged. Special items for FY 2022/23 are expected to increase by DKK 50 million due to transaction related costs (advisory fees).FIH Partners acted as transaction advisors, Kromann Reumert acted as Lead Legal Advisors, and PWC acted as financial advisors to Coloplast. Danske Bank will act as Sole Global Coordinator in connection with the equity capital raise and Joint Bookrunner together with Nordea. J.P. Morgan acted as exclusive financial advisor to Kerecis.
공시 • May 11Coloplast A/S Provides Earnings Guidance for the Fiscal 2023Coloplast A/S provided earnings guidance for the full fiscal year 2022/2023. For the period, the company reports organic revenue growth is now expected around 8% in constant exchange rates, from 7-8% previously. Reported growth in DKK is now expected to be 8-9%, from previously 9-10%, due to negative impact from currencies. Consequently, the reported EBIT margin is now expected in the 28-29% range, from previously 28-30%.
공시 • Feb 04Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract InfectionsColoplast launches male catheter designed to reduce the risk of urinary tract infections. The new intermittent catheter Luja addresses important risk factors for urinary tract infections, a significant burden for people using intermittent catheters as well as healthcare systems as a whole. Urinary tract infections represent a significant challenge for people who use intermittent catheters to empty their bladder. This includes people living with spinal cord injury, multiple sclerosis, or spina bifida. On average, intermittent catheter users have 2-3 urinary tract infections per year1-3, which can lead to serious health complications4, have a significant impact on quality of life2, and result in hospitalisation5-9, thereby putting pressure on local healthcare systems. Coloplast is now launching Luja, the first and only male catheter featuring 80+ micro-holes, aiming to address important UTI risk factors1 linked to intermittent catheterisation. Flow stops and blockage of the catheter eyelets during emptying increase the risk of leaving residual urine behind in the bladder. Residual urine increases the risk of bacteria growth and is a well-known UTI risk factor. The launch of Luja begins this month, February, in Denmark and Finland, and the product is expected to be available across Coloplast’s key markets over the next 12 months. Coloplast is currently conducting two pivotal clinical studies to document and demonstrate the benefits of Luja. The results are expected to be publicly available within the next few months. In 2021/22, the global market for continence care products was worth an estimated 15-16 billion DKK with an underlying annual market growth of 5-6%. Coloplast is the global market leader in continence care, and the company continues to outgrow the market and take market share. The launch of Luja is expected to contribute to Coloplast’s growth trajectory and help solidify the company’s global market leader position. Luja has close to no flow stops and complete bladder emptying is defined as <10 mL (CP353, NCT05485922).
공시 • Feb 03Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23Coloplast A/S provided earnings guidance for the Fiscal Year 2022/23. For the period, Organic revenue growth is expected at 7% to 8% in constant exchange rates. Reported EBIT margin before special items is still expected at 28% to 30%, impacted by increasing input costs, especially raw materials and electricity in Hungary, partly offset by leverage, efficiency gains and prudent management of operating costs.
공시 • Sep 09+ 4 more updatesColoplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023Coloplast A/S announced that they will report fiscal year 2023 results on Nov 09, 2023